RVMD Revolution Medicines, Inc.: Enterprise Value-to-Revenue Multiple

Official company branding of revmed.com (RVMD)

Revolution Medicines (RVMD) complies with environmental regulations regarding bio-waste disposal. The EV-to-revenue multiple visualizes the purity of market value excluding debt load, where 162196.29 determines the latest valuation metric. The business relies on the unique development of RAS protein inhibitors to combat advanced cancer. The chronic nature of these pathologies ensures stable, multi-year demand for patented therapy methods.

RevMed (RVMD) - Company Value to Revenue from 11/23/2025 to 11/20/2026

Revolution Medicines Corp - analytical breakdowns and key metrics (RVMD)

- share price and expert price forecast:
- cash balance and cash flow data:
Initial company analysis:RVMD, revmed.com
Manufactured products of RevMed

Amid intense competition in the development of anti-cancer drugs, the current enterprise value-to-revenue multiple of Revolution Medicines (RVMD) allows for an assessment of market expectations for future therapies, excluding debt obligations. This ratio compares the total business value to its annual turnover, helping investors determine the degree of asset overvaluation and the risks of correction in the event of potential clinical trial failures.

Competitor analysis

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Ascentage Pharma Group International (AAPG)|Enterprise Value-to-Revenue Ratio CG Oncology, Inc.|Enterprise Value-to-Revenue Multiple UroGen Pharma Corp URGN|EV/Sales Multiple BCAX|Personalis, Inc. - Company Value to Revenue Ratio|Erasca - Company Value to Revenue|Business Value to Revenue DCTH|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio